您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Pyrroloquinoline quinone
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Pyrroloquinoline quinone
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Pyrroloquinoline quinone图片
CAS NO:72909-34-3
包装与价格:
包装价格(元)
100 mg电议
1 mL*10 mM(in DMSO)电议

产品介绍
Pyrroloquinoline quinone 是氧化还原辅助因子,一种阴离子型氧化还原循环原醌。它是哺乳动物的必需营养素,对免疫功能很重要。它最初是从嗜甲基细菌的培养物中分离的,也存在于哺乳动物的组织。

产品描述

Pyrroloquinoline quinone (PQQ), as a well-known redox enzyme cofactor, PQQ can protect NS/PCs against glutamate toxicity associated with ROS-mediated mitochondrial pathway,

体外活性

Pyrroloquinoline quinone(PQQ) pretreatment showed its significant effect on protecting NS/PCs against glutamate-induced apoptosis/necrosis.?PQQ neuroprotection was associated with the decrease of intracellular reactive oxygen species (ROS) production, the increase of glutathione (GSH) levels, and the decrease of caspase-3 activity.?In addition, pretreatment with PQQ also significantly enhanced the activities of superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) in the NS/PCs exposed to glutamate[1].

体内活性

Pyrroloquinoline quinone(PQQ), a natural anti-oxidant present in a wide variety of human foods, exerted potent anti-fibrotic and ROS-scavenging activity in Balb/C mouse models of liver fibrosis. The antioxidant activity of PQQ was involved in the modulation of multiple steps during liver fibrogenesis, including chronic liver injury, hepatic inflammation, as well as activation of hepatic stellate cells and production of extracellular matrix. PQQ also suppressed the up-regulation of RACK1 in activated HSCs in vivo and in vitro. PQQ suppresses oxidative stress and liver fibrogenesis in mice[2].

动物实验

Healthy male Balb/C mice of 4–6 week were used to induce liver fibrosis and isolate primary HSCs.?The animals were obtained from SLAC Laboratory Animal Corp in SPF microbiological status.?All mice were maintained at 25°C with a 12 h dark/light cycle and completely randomly grouped.?For thioacetamide (TAA)-induced liver fibrosis, which has been shown to be closely resemble the panlobular and parenchymal fibrosis that is found in most human chronic liver disease , TAA was given by intraperitoneal injection ?at 200 mg/kg body weight 3 times each week for 8 weeks.?For bile duct ligation (BDL)-induced liver fibrosis, BDL was performed according to previous report , and mice were sacrificed 2 weeks later.?Administration of PQQ started on the second day when TAA was firstly given or BDL was performed, and PQQ was given at the dose of 0.3 mg/kg or 1 mg/kg by gastrogavage administration daily before mice were sacrificed.?Silymarin (150 mg/kg) was used as the positive control by gastrogavage administration daily.?Total number of 405 mice were used.?Mice were sacrificed by cervical dislocation under anesthesia[2].

Cas No.

72909-34-3

分子式

C14H6N2O8

分子量

330.208

储存和溶解度

DMSO:10 mM
Powder: -20°C for 3 years
In solvent: -80°C for 2 years